Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 4/20 | 0.35 |
| ▸ | CDK7 | P50613 | 9/20 | 0.34 |
| ▸ | CCNH | P51946 | 9/20 | 0.34 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.34 |
| ▸ | CDK2 | P24941 | 4/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23529884 | 0.83 | XDH (0.36) | HAVCR2CDK7CCNHMNAT1CDK2 | |
| SCHEMBL18510365 | 0.81 | CDK7 (0.34) | HAVCR2CDK7CCNHMNAT1CDK2 | |
| SCHEMBL15224509 | 0.79 | LMNA (0.36) | HAVCR2CDK7CCNHMNAT1CDK2 | |
| SCHEMBL21741564 | 0.78 | CDK2 (0.39) | HAVCR2CDK7CCNHMNAT1CDK2 | |
| SCHEMBL29174858 | 0.77 | HTR2C (0.51) | CDK7CCNHMNAT1CDK2CCNE1 | |
| SCHEMBL18520998 | 0.71 | ALDH1A1 (0.39) | CDK2GSK3B | |
| SCHEMBL24236930 | 0.71 | HTR2C (0.31) | — | |
| SCHEMBL28459634 | 0.69 | CDK7 (0.33) | CDK7CCNHMNAT1CDK2CCNE1 | |
| SCHEMBL25808499 | 0.69 | KDM4E (0.32) | — | |
| SCHEMBL23228203 | 0.68 | MEN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| CN-113272305-A | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2021-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | HAVCR2 695/4885CDK7 1500/4885CCNH 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.